Compare OneSpan Inc (OSPN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Sanofi SA — how do they compare? OneSpan Inc trades at $18.22 (market cap $662.97M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 143.6× OneSpan Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Sanofi SA for 94 Days on average.
| OSPN | SNY | |
|---|---|---|
Market Cap | $662.97M | $95.18B |
Volume | 616,882 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $18.42 | $52.34 |
52-Week Low | $10.15 | $39.51 |
Typical Hold Time | 18 Days | 94 Days |
Enterprise Value | $632.05M | $114.48B |
Dividend Yield | 2.89% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSPN trades at $18.22, up 2.94% today, with a bullish technical signal from moving averages and recent earnings beats. The company shows strong profitability with a 27.76% net income margin and a reasonable P/E of 10.16. Analyst consensus is strongly positive with 10 buy ratings. Recent news highlights investor attention and a new product launch, DigipassONE, supporting growth prospects.
The outlook for OSPN is favorable given consistent earnings outperformance and solid fundamentals, though negative net cash flow and competitive pressures pose risks. Upside potential hinges on execution of its subscription revenue growth strategy and market adoption of new authentication solutions.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
